1-6 of 6
Lu Xu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract GS02-01: Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01

Aditya Bardia, Komal Jhaveri, Seock-Ah Im, Michelino De Laurentiis, Binghe Xu, Sonia Pernas, Giuliano Borges, David Cescon, Masaya Hattori, Yen-Shen Lu, Noelia Martínez-Jáñez, Erika Hamilton, Shusen Wang, Junji Tsurutani, Kevin Kalinsky, Lu Xu, Sabrina Khan, Neelima Denduluri, Hope Rugo, Barbara Pistilli
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): GS02-01.
https://doi.org/10.1158/1538-7445.SABCS23-GS02-01
Published: 02 May 2024
View article titled, Abstract GS02-01: Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01
Journal Articles

Abstract PO3-05-10: Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multi-center, open-label, single-arm, phase II study

PeiJian Peng, Xiao-Lu Xu, Jin-Cai Zhong, Jin-Hui Ye, Zhi-Hui Wang, Hong Wang, Hong Lin, Cai-Wen Du, Guorong Zou, Jie Ouyang, Ying-Ying Shi, Fei Xu, Geng-Sheng Yu, Yong-Kui Lu, Yong-Xia Wang, Shi-En Cui, Lu-Zhen Li
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-05-10.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-05-10
Published: 02 May 2024
View article titled, Abstract PO3-05-10: Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multi-center, open-label, single-arm, phase II study
Journal Articles

Abstract 2964: Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody BDC-3042

Justin A. Kenkel, Fang Xiao, Po Y. Ho, Jess L. Nolin, Rishali K. Gadkari, Laughing Bear Torrez, David T. Omstead, Katelynn A. McEachin, Jason Ptacek, Rachel Grgich, Cecelia I. Pearson, Stefan Chun, Cindy L. Kreder, Karla A. Henning, Han K. Kim, Lu Xu, Steven J. Chapin, Michael N. Alonso, Shelley E. Ackerman
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2964.
https://doi.org/10.1158/1538-7445.AM2023-2964
Published: 04 April 2023
View article titled, Abstract 2964: Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody BDC-3042
Journal Articles

Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma

Ming-Yu Luo, Ye Zhou, Wei-Ming Gu, Cheng Wang, Ning-Xiang Shen, Jiang-Kai Dong, Hui-Min Lei, Ya-Bin Tang, Qian Liang, Jing-Hua Zou, Lu Xu, Pengfei Ma, Guanglei Zhuang, Ling Bi, Ling Xu, Liang Zhu, Hong-Zhuan Chen, Ying Shen
Journal: Cancer Research
Cancer Res (2022) 82 (19): 3516–3531.
https://doi.org/10.1158/0008-5472.CAN-21-4074
Published: 04 October 2022
View article titled, Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma
Open the PDF for Metabolic and Nonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFR Inhibitor Resistance and Drive Progression in Lung Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract 290: A novel function of HGF in the activation of Chk1 phosphorylation in colon cancer cells

Na Song, Xiaofang Che, Xiujuan Qu, Lu Xu, Kezuo Hou, Yunpeng Liu
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 290.
https://doi.org/10.1158/1538-7445.AM2017-290
Published: 01 July 2017
View article titled, Abstract 290: A novel function of HGF in the activation of Chk1 phosphorylation in colon cancer cells
Journal Articles

Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Lu Xu, Eiki Kikuchi, Chunxiao Xu, Hiromichi Ebi, Dalia Ercan, Katherine A. Cheng, Robert Padera, Jeffrey A. Engelman, Pasi A. Jänne, Geoffrey I. Shapiro, Takeshi Shimamura, Kwok-Kin Wong
Journal: Cancer Research
Cancer Res (2012) 72 (13): 3302–3311.
https://doi.org/10.1158/0008-5472.CAN-11-3720
Published: 01 July 2012
View article titled, Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET
Open the PDF for Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET in another window
Includes: Supplementary data